MAPT and Alzheimer disease: The conformational stability assay (CSA) was derived from previously validated protocols for differentiating distinct conformers of human and animal prions, amyloid beta, and tau [4,35–45] and data in the frontal cortex (Fig 1B) correspond to the variable conformational stability of AD brain-derived tau aggregates we reported in the hippocampal cortex previously [3].